| Type | Condition | Trial / Sponsor | Description |
| Interventional | Solid Tumors | 1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors Mirati Therapeutics, Inc. |
<b>Full Title</b><br> 1719-001: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion <br><br> <b>Study Treatment</b><br> Oral PRMT5 inhibitor MRTX1719 <br><br> <b>Eligibility/Info</b><br> Phase 1 - advanced MTAP deleted solid tumor that has continued to grow despite treatment with standard anti-cancer therapies. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Breast Cancer | ACE-Breast-03: ARX788 in HER2-positive, Metastatic Breast Cancer Subjects Previously Treated with T-DXd Ambrx, Inc. |
<b>Full Title</b><br> Protocol ACE-Breast-03: A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd <br><br> <b>Study Treatment</b><br> HER2 targeting antibody-drug conjugate ARX788 <br><br> <b>Eligibility/Info</b><br> HER2-positive metastatic breast cancer treated with up to 5 prior lines of therapy in the metastatic setting, one of which included trastuzumab deruxtecan. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Non-Small Cell Lung Cancer | ARTEMIA: Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor OSE Immunotherapeutics |
<p> <b>Full Title</b><br> Protocol OSE2101C302: A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor </p> <p> <b>Study Treatment</b><br> OSE2101, a peptidic cancer vaccine, given in combination with chemotherapeutic agent docetaxel </p> <p> <b>Eligibility/Info</b><br> Participants must have a history of an advanced/metastatic non-small cell lung cancer that has progressed after at least 24 weeks of first line treatment with immunotherapy. </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Breast Cancer | ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer Gilead Sciences, Inc. |
<b>Full Title</b><br> Protocol GS-US-595-6184: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy <br><br> <b>Study Treatment</b><br> Arm A: Anti-TROP2 antibody-drug conjugate sacituzumab govitecan + pembrolizumab<br> Arm B: pembrolizumab +/- capecitabine <br><br> <b>Eligibility/Info</b><br> Non-metastatic triple negative breast cancer treated with neoadjuvant systemic therapy followed by surgery. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Cachexia | AV-380-22-102: A Dose Escalation Study of GDF-15 Inhibitor AV-380 in Metastatic Cancer Patients with Cachexia AVEO Pharmaceuticals, Inc. |
<b>Full Title</b><br> AV-380-22-102: A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels <br><br> <b>Study Treatment</b><br> Intravenous GDF-15 inhibitor AV-380 <br><br> <b>Eligibility/Info</b><br> Advanced or metastatic cancer currently being treated with standard of care systemic therapy. Must have cachexia as defined by the Fearon criteria as one of:<br> - Weight loss >5% over past 6 months (in absence of simple starvation), or<br> - BMI < 20 kg/m<sup>2</sup> and any degree of weight loss >2%, or<br> - Sarcopenia and >2% weight loss <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Colon Cancer | AZUR-2: Perioperative Dostarlimab in Patients with dMMR/MSI-H Resectable Colon Cancer GlaxoSmithKline |
<b>Full Title</b><br> Protocol 219606: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer <br><br> <b>Study Treatment</b><br> Perioperative treatment with anti-PD1 monoclonal antibody dostarlimab <br><br> <b>Eligibility/Info</b><br> - Pathologically confirmed resectable (T4N0 or Stage III) colon adenocarcinoma<br> - Mismatch repair deficient or MSI-High<br> - No history of treatment <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Non-Small Cell Lung Cancer | AndroMETa-Lung-536: Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC AbbVie |
<p> <b>Full Title</b><br> Protocol M24-536: An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations </p> <p> <b>Study Treatment</b><br> c-MET targeting antibody-drug conjugate telisotuzumab adizutecan in combination with investigational anti-PD-1 antibody budigalimab or standard chemo/immunotherapy. </p> <p> <b>Eligibility/Info</b><br> <p> Part 1: <ul> <li>1L Cohort: No prior systemic therapy in the advanced/metastatic setting</li> <li>2L Cohort: Participants without an actionable genetic alteration must have progressed on (or be considered ineligible for) platinum-based chemotherapy or immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy). Participants with an actionable genetic alteration (other than EGFR) must have progressed on (or be considered ineligible for) anti-cancer therapy targeting driver gene alteration or platinum-based chemotherapy.</li> </ul> </p> <p> Part 2: <ul> <li>Participants must have had no prior systemic therapy for locally advanced or metastatic NSCLC.</li> </ul> </p> </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Chronic Lymphocytic Leukemia | BGB-11417-204: Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia BeOne Medicines |
<p> <b>Full Title</b><br> BGB-11417-204: A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia </p> <p> <b>Study Treatment</b><br> Zanubrutinib +/- Sonrotoclax<br> BGB-11417 (sonrotoclax) is a highly potent and selective Bcl-2 protein inhibitor.<br> Zanubrutinib is a more selective covalent BTK inhibitor. </p> <p> <b>Eligibility/Info</b><br> Untreated chronic lymphocytic leukemia that requires first line systemic therapy. </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Breast Cancer | Breast Cancer | BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer BriaCell Therapeutics Corporation |
<b>Full Title</b><br> BC-IMT-04: Randomized, Open-label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer <br><br> <b>Study Treatment</b><br> GM-CSF-secreting breast cancer vaccine SV-BR-1-GM in combination with anti-PD1 immunotherapy retifanlimab-dlwr <br><br> <b>Eligibility/Info</b><br> Eligible patients will have one of the following prior treatment histories: <br> - <u>HR+/HER2-</u>: Previously treated with at least 2 prior chemotherapy or targeted therapy regimens<br> - <u>HER2+</u>: Previously treated with at least 3 treatment regimens including 2 anti-HER2 therapies<br> - <u>TNBC</u>: Exhausted all standard of care therapies known to confer clinical benefit<br> - <u>HER2-Low</u>: Previously treated with at least 1 anti-HER2 therapy in addition to the appropriate HR status therapies<br> - <u>Actionable Mutation</u>: Patients with an actionable mutation must have been treated with appropriate targeted therapy <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Non-Small Cell Lung Cancer | COPERNICUS: A Phase 2b, Open-Label, Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment Janssen Research & Development, LLC |
<p> <b>Full Title</b><br> Protocol 61186372NSC2012: A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer </p> <p> <b>Study Treatment</b><br> Amivantamab, a bispecific antibody targeting EGFR and MET in combination with lazertinib, an EGFR tyrosine kinase inhibitor. </p> <p> <b>Eligibility/Info</b><br> Eligible patients will have an advanced/metastatic non-small cell lung cancer with an EGFR exon 19 deletion or EGFR L858R mutation and will not have received systemic anticancer therapy in the advanced/metastatic setting. </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Observational | Non-Small Cell Lung Cancer | CYBRID-01: Observational lung trial to collect tissue to train and validate a live tumor diagnostic platform Elephas Biosciences Corporation |
<b>Full Title</b><br> Protocol ELEP-2022-CYBRID-01: Observational lung trial to collect tissue to train and validate a live tumor diagnostic platform <br><br> <b>Study Treatment</b><br> The study includes one scheduled on-site visit for baseline enrollment. Biopsy(ies) will be collected from all enrolled subjects. The biopsy should be collected as an additional pass(es) during a standard of care core needle biopsy. <br><br> <b>Eligibility/Info</b><br> - Patients with suspected metastatic non-small cell lung cancer that will be undergoing a core biopsy at the Lake Success Medical Oncology office. <br><br> Elephas will train and validate its cancer diagnostic platform for prediction of drug response, with a focus on the checkpoint inhibitor pembrolizumab (Keytruda). <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Endometrial Cancer | DB-1303-O-1001: A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors DualityBio Inc. |
<b>Full Title</b><br> A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors <br><br> <b>Study Treatment</b><br> HER2 targeting antibody drug conjugate DB-1303/BNT323 <br><br> <b>Eligibility/Info</b><br> Cohort 2p: HER2-low to -positive metastatic endometrial cancer previously treated with platinum chemotherapy and immunotherapy. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Prostate Cancer | Debio 4228-201: Study of Extended Release GnRH in Newly Diagnosed Locally Advanced or Metastatic Prostate Cancer Debiopharm International SA |
<b>Full Title</b><br> Protocol Debio 4228-201: A Phase 2, randomized, open-Label, dose-finding study of Debio 4228, an extended-release formulation of gonadotropin-releasing hormone antagonist in participants with locally advanced/metastatic prostate cancer <br><br> <b>Study Treatment</b><br> Debio 4228 - a 12 week extended release gonadotropin-releasing hormone antagonist (GnRH) <br><br> <b>Eligibility/Info</b><br> - Locally advanced or metastatic prostate cancer<br> - No prior androgen deprivation therapy (ADT) or ≤6 months of treatment with ADT<br> - Eligible for continuous ADT <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Breast Cancer | ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor Stemline Therapeutics, Inc. |
<b>Full Title</b><br> Protocol STML-ELA-0222: A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer <br><br> <b>Study Treatment</b><br> <u>Arm A</u>: Elacestrant + Alpelisib<br> <u>Arm B</u>: Elacestrant + Everolimus<br> <u>Arm C</u>: Elacestrant + Palbociclib<br> <u>Arm D</u>: Elacestrant + Ribociclib <br><br> <b>Eligibility/Info</b><br> Eligible patients will have ER+, HER2- metastatic breast cancer that has not been treated with chemotherapy in the metastatic setting but that has progressed after up to 2 prior lines of hormonal therapy that included a CDK4/6 inhibitor. Patients in arm A (alpelisib combination arm) must also have a documented PIK3CA mutation. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Breast Cancer | EvoPAR-Breast01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative, BRCA1, BRCA2, or PALB2m Advanced Breast Cancer AstraZeneca |
<p> <b>Full Title</b><br> Protocol D9722C00001: A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer </p> <p> <b>Study Treatment</b><br> Study participant treatment will be randomized 2:2:1 between the following 3 treatment arms: <ul> <li>Arm 1: PARP1 inhibitor saruparib in combination with next generation selective estrogen receptor degrader camizestrant</li> <li>Arm 2: Physician's choice CDK4/6 inhibitor in combination with standard endocrine therapy</li> <li>Arm 3: Physician's choice CDK4/6 inhibitor in combination with camizestrant</li> </ul> </p> <p> <b>Eligibility/Info</b><br> Advanced or metastatic hormone receptor positive, HER2 negative breast cancer with a loss of function mutation in BRCA1, BRCA2, or PALB2. Participants must not have been treated with systemic anti-cancer therapy in the advanced/metastatic setting. </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Just In Time | Central Nervous System Cancer | F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy Fore Biotherapeutics |
<b>Full Title</b><br> F8294-201b: A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations <br><br> <b>Study Treatment</b><br> Oral BRAF inhibitor FORE8394 in combination with cobicistat <br><br> <b>Eligibility/Info</b><br> For the treatment of patients with a BRAF V600E mutant CNS primary malignancy that has recurred or continued to grow after at least 1 prior line of therapy including radiation. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. |
| Interventional | Breast Cancer | First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer Regor Pharmaceuticals Inc. |
<b>Full Title</b><br> First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer <br><br> <b>Study Treatment</b><br> RGT-419B, an oral CDK2/4/6 inhibitor <br><br> <b>Eligibility/Info</b><br> - HR+, HER2- breast cancer with progressive disease after at least 1 line of therapy including a CDK4/6 inhibitor <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Colorectal Cancer | INTRINSIC: A Multi-Arm Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer Hoffmann-La Roche |
<p> <b>Full Title</b><br> Protocol WO42758: A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer </p> <p> <b>Study Treatment</b><br> Oral KRAS G12C inhibitor Divarasib in combination with standard of care chemotherapy regimen FOLFOX or FOLFIRI </p> <p> <b>Eligibility/Info</b><br> <ul> <li>Stage IV colon or rectal adenocarcinoma</li> <li>KRAS G12C mutation and the absence of another oncogenic mutation</li> <li>No prior systemic therapy in the advanced/metastatic setting</li> </ul> </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Non-Small Cell Lung Cancer | KRAScendo-1: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Hoffmann-La Roche |
<p> <b>Full Title</b><br> Protocol BO45217: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer </p> <p> <b>Study Treatment</b><br> Divarasib, an oral KRAS G12C inhibitor </p> <p> <b>Eligibility/Info</b><br> Eligible participants will have an unresectable/metastatic non-small cell lug cancer with a KRAS G12C mutation. Participants must have previously been treated in the metastatic setting with platinum-based doublet chemotherapy as well as a PD-(L)1 inhibitor. Participants cannot have been treated with a KRAS G12C or pan-RAS inhibitor prior to enrolling in this clinical trial. </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Non-Small Cell Lung Cancer | KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation Mirati Therapeutics, Inc. |
<b>Full Title</b><br> Protocol 849-017: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation <br><br> <b>Study Treatment</b><br> KRAS G12C inhibitor adagrasib in combination with standard chemo/immunotherapy. <br><br> <b>Eligibility/Info</b><br> Unresectable or metastatic KRAS G12C mutant non-squamous non-small cell lung cancer that has not been treated in the metastatic setting. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Non-Small Cell Lung Cancer | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC NovoCure GmbH |
<p> <b>Full Title</b><br> EF-44: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer </p> <p> <b>Study Treatment</b><br> 1:1 randomization between treatment with standard of care chemo and immunotherapy +/- the addition of a Tumor Treatment Fields device. </p> <p> <b>Eligibility/Info</b> <ul> <li>Stage IV squamous or non-squamous non-small cell lung cancer</li> <li>No history of systemic therapy for advanced or metastatic non-small cell lung cancer</li> <li>No targetable oncogenic driver mutations</li> </ul> </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Multiple Myeloma | M22-574: Study of Treatment with Bispecific Antibody ABBV-383 in Relapsed/Refractory Multiple Myeloma After at Least 2 Prior Lines of Therapy AbbVie |
<b>Full Title</b><br> Protocol M22-574: A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) <br><br> <b>Study Treatment</b><br> BCMAxCD3 bispecific antibody ABBV-383 vs standard approved therapy <br><br> <b>Eligibility/Info</b><br> Relapsed/refractory multiple myeloma treated with at least 2 prior lines of therapy. Prior therapy must have included an immunomodulating agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a> |
| Interventional | Non-Small Cell Lung Cancer | MARIGOLD: A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Amgen |
<p> <b>Full Title</b><br> Protocol 20210033: A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer </p> <p> <b>Study Treatment</b><br> Pembrolizumab biosimilar candidate ABP 234 + platinum doublet chemotherapy vs pembrolizumab + platinum doublet chemotherapy </p> <p> <b>Eligibility/Info</b><br> Metastatic non-small cell lung cancer without prior systemic therapy in the advanced/metastatic setting. </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Hyperkalemia/Chronic Kidney Disease | NYH-01: Hyperkalemia/Chronic Kidney Disease Relypsa |
<b>Description</b><br> This study aims to investigate the feasibility of increasing dietary consumption of a rich variety of fruits and vegetables (including those that are potassium-rich) in patients with chronic kidney disease through use of nutritional counselling and hyperkalemia management with patiromer <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nyhealth.com/locations/ny_health_nephrology">NY Health Nephrology - Port Jefferson Station</a><br> |
| Interventional | Colorectal Cancer | OrigAMI-2: Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Cancer Janssen Research & Development, LLC |
<p> <b>Full Title</b><br> Protocol 61186372COR3001: A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer </p> <p> <b>Study Treatment</b><br> EGFRxMET bispecific antibody Amivantamab vs Cetuximab<br> Given in combination with either FOLFOX or FOLFIRI chemotherapy </p> <p> <b>Eligibility/Info</b><br> KRAS, NRAS, and BRAF wild type unresectable or metastatic left sided colorectal cancer that has not previously been treated with systemic therapy in the metastatic setting. </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Colorectal Cancer | OrigAMI-3: Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Janssen Research & Development, LLC |
<p> <b>Full Title</b><br> Protocol 61186372COR3002: A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy </p> <p> <b>Study Treatment</b><br> EGFRxMET bispecific antibody Amivantamab vs Cetuximab or Bevacizumab<br> Given in combination with the FOLFIRI chemotherapy regimen </p> <p> <b>Eligibility/Info</b><br> KRAS, NRAS, and BRAF wild type unresectable or metastatic colorectal cancer previously treated with a fluoropyrimidine and oxaliplatin in the metastatic setting and with no history of treatment with an EGFR inhibitor or irinotecan. </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Chronic Myeloid Leukemia | POLARIS-2: Study of Olverembatinib (HQP1351) in Patients With CP-CML Ascentage Pharma Group Inc. |
<p> <b>Full Title</b><br> Protocol HQP1351CG301: A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia </p> <p> <b>Study Treatment</b><br> Third-generation BCR-ABL1 tyrosine kinase inhibitor Olverembatinib vs bosutinib </p> <p> <b>Eligibility/Info</b><br> Eligible patient must have chronic phase chronic myeloid leukemia without a history of accelerated or blastic phase. <br> Part A: Treatment with at least two prior TKIs and confirmed absence of T315I and V229L mutations<br> Part B: Confirmed presence of T315I mutation, prior treatment with at least 1 TKI, and lack of other effective/tolerable therapies </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Advanced Solid tumors | Phase 1 Study of SGN-B6A in Advanced Solid Tumors Seagen Inc. |
<b>Full Title</b><br> A Phase 1 Study of SGN-B6A in Advanced Solid Tumors This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. <br><br> <b>Study Treatment</b><br> The study will have four parts:<br><br> <b>Part A</b> of the study will find out how much sigvotatug vedotin should be given to participants.<br><br> <b>Part B</b> will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors.<br> Sigvotatug vedotin monotherapy <br><br> <b>Part C</b> of the study will find out how safe sigvotatug vedotin is in combination with these other drugs.<br> Combination therapy in NSCLC, HNSCC, ESCC<br> Sigvotatug vedotin + pembrolizumab (Keytruda) +/- (carboplatin or cisplatin) <br><br> <b>Part D</b> will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors.<br> Combination therapy in 1L NSCLC<br> Sigvotatug vedotin + pembrolizumab (Keytruda) +/- (carboplatin)<br> or<br> Combination therapy in 1L HNSCC<br> Sigvotatug vedotin + pembrolizumab (Keytruda) +/- (carboplatin or cisplatin) <br><br> <b>Eligibility/Info</b><br> • Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on study part).<br> • Non-small cell lung cancer (NSCLC)<br> • Head and neck squamous cell cancer (HNSCC)<br> • Advanced HER2-negative breast cancer<br> • Esophageal squamous cell carcinoma (ESCC)<br> • Esophageal/Gastro-esophageal junction adenocarcinoma (EAC/GEJ)<br> • Cutaneous squamous cell cancer (cSCC)<br> • Exocrine pancreatic adenocarcinoma<br> • Bladder cancer<br> • Cervical cancer<br> • Gastric cancer<br> • High grade serous ovarian cancer (HGSOC)<br> • Participants should have a tumor site accessible for biopsy or archival biopsy collected within 90 days prior to first dose of study drug may be used.<br> • Measurable disease per the RECIST v1.1 at baseline<br> Exclusion Criteria<br> • History of another malignancy within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.<br> • Known active central nervous system metastases. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Solid Tumors or Multiple Myeloma | QXL138AM-001: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma Nammi Therapeutics Inc |
<p> <b>Full Title</b><br> Protocol QXL138AM-001: A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma </p> <p> <b>Study Treatment</b><br> QXL138AM is interferon alpha 2 (IFNα2) masked immunocytokine (MIC) fused to antibody targeting CD138 </p> <p> <b>Eligibility/Info</b> <ul> <li><b>Solid tumors</b>: Metastatic ovarian, pancreatic, urothelial, renal, hepatocellular, gastrointestinal (GI), lung, prostate, or breast cancer that has continued to grow after standard systemic therapies.</li> <li><b>Multiple Myeloma</b>: Multiple myeloma that has continued to grow after treatment with at least 3 lines of therapy that included an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulating agent. </li> </ul> </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Diffuse Large B-Cell Lymphoma | SKYGLO: Glofitamab in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma Hoffmann-La Roche |
<b>Full Title</b><br> Protocol GO44145: A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma <br><br> <b>Study Treatment</b><br> CD20xCD3 bispecific antibody glofitamab in combination with Pola-R-CHP vs Pola-R-CHP alone <br><br> <b>Eligibility/Info</b><br> Untreated CD20-positive Large B-Cell Lymphoma of one of the following types:<br>       - DLBCL, not otherwise specified (NOS) including germinal centre B-cell type, activated B-cell type<br>       - T-cell/histiocyte-rich large B-cell lymphoma<br>       - Epstein-Barr virus-positive DLBCL, NOS<br>       - Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8 positive DLBCL<br>       - DLBCL/HGBCL with MYC and BCL2 rearrangements<br>       - HGBCL, NOS <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Multiple Myeloma | SUCCESSOR-1: A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Celgene Corporation |
<b>Full Title</b><br> Protocol CA057-001: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) <br><br> <b>Study Treatment</b><br> 1:1 randomization between the following treatment arms: <br> Arm A: Mezigdomide (modulator of the E3 ubiquitin ligase complex containing cereblon) in combination with Bortezomib and Dexamethasone<br> Arm B: Pomalidomide, Bortezomib, and Dexamethasone <br><br> <b>Eligibility/Info</b><br> Relapsed or refractory multiple myeloma that has continued to grow or that has come back after 1-3 prior lines of antimyeloma systemic therapy that included lenalidomide. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Non-Small Cell Lung Cancer | TRITON: First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology AstraZeneca LP |
<p><b>Full Title</b><br> A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON) <p> <b>Study Treatment</b><br> Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment <p> <b>Eligibility/Info</b> <ul> <li>Histologically or cytologically documented Stage IV non-squamous NSCLC not amenable to curative surgery or radiation.</li> <li>STK11 or KEAP1 or KRAS mutations. </li> <ul> <li>Co-mutations are also allowed (STK11 and KRAS mutations, STK11 and KEAP1 mutations, or KEAP1 and KRAS mutations).</li> </ul> <li>Participants must have tumors that lack activating EGFR mutations (eg, exon 19 deletion or exon 21 L858R, exon 21 L861Q, exon 18 G719X, exon 20 insertions, or exon 20 S768I mutation) and ALK fusions.</li> <li>No prior chemotherapy or any other systemic therapy for metastatic NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred >6 months from end of last therapy</li> <li>No prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anti-cancer vaccines, within 12 months to randomization.</li> </ul> <p><b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>.</p> <p><b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a> </p> |
| Interventional | Non-Small Cell Lung Cancer | TeLuRide-005: EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer Eikon Therapeutics |
<b>Full Title</b><br> EIK1001-005: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer <br><br> <b>Study Treatment</b><br> Toll-Like Receptor 7 and 8 co-agonist, EIK1001 given in combination with chemotherapy and pembrolizumab <br><br> <b>Eligibility/Info</b><br> - Stage IV squamous or non-squamous non-small cell lung cancer<br> - No history of systemic therapy in the advanced/metastatic setting<br> - No actionable mutation <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Non-Interventional | Cancer Diagnosis | [Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients Memorial Sloan Kettering Cancer Center |
<b>Full Title</b><br> Protocol 12-245: Genomic Profiling in Cancer Patients <br><br> <b>Description</b><br> Genetic testing for patients with a cancer diagnosis or that are undergoing a work up to establish a potential cancer diagnosis. The primary objective of the trial is to determine the frequency of “actionable” oncogenic mutations in patients with solid or hematologic cancers being evaluated for treatment. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. |
| Non-Interventional | Various Indications | [Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) Precision for Medicine |
<b>Full Title</b><br> Protocol PMDx060: Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. |
| Non-Interventional | Solid Tumors | [Sample Collection] Collection and Distribution of Biofluids for Research Purposes Bluestar Genomics |
<b>Description</b><br> Blood sample collection study for patients with newly diagnosed, untreated solid tumors excluding prostate and melanoma. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href "tel:631-675-5075">631-675-5075.</a> |
| Non-Interventional | Solid Tumors | [Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2) Exact Sciences Thrive LLC |
<b>Full Title</b><br> Protocol THR-CS-001: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) <br><br> <b>Eligibility</b><br> Observational, sample collection study for patients with a new, untreated diagnosis of one of the following malignancies: <br> Breast, lung, colorectal, bladder, uterine, kidney/renal pelvis, pancreatic, liver, stomach, ovarian, esophageal cancer, head and neck squamous cell, thyroid, small intestine, cervical, anal, vulva, or testis <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. |
| Non-Interventional | Various Indications | [Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) SERATRIALS, LLC. |
<b>Full Title</b><br> Protocol SeraTrials-05035 - Blood sample collection study with constantly changing set of available cohorts. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. |
| Non-Interventional | Solid Tumors | [Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening Freenome Holdings Inc. |
<b>Full Title</b><br> Protocol FRM-008: The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening <br><br> <b>Eligibility/Info</b><br> Blood draw study for patients with solid tumors that have not yet received treatment. <br><br> Freenome is developing blood-based screening tests for multiple cancer types using its multiomics platform. The current protocol targets enrolling subjects with specified types of cancers... for the development of multicancer products. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. |